Agios Pharmaceuticals (AGIO) Cash & Current Investments (2012 - 2026)
Agios Pharmaceuticals (AGIO) posted Cash & Current Investments of $737.0 million for Q1 2026, down 13.74% on a QoQ basis from $854.4 million in Q4 2025, and down 17.5% year-over-year from $893.4 million in Q1 2025.
Agios Pharmaceuticals (AGIO) Cash & Current Investments (2012 - 2026) Analysis & Trends
Agios Pharmaceuticals' Cash & Current Investments history runs 15 years deep, the most recent figure standing at $737.0 million for Q1 2026.
- Quarterly Cash & Current Investments fell 17.5% year-over-year to $737.0 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $737.0 million (down 17.5% YoY) and the FY2025 annual result came in at $854.4 million, down 4.4% from the prior year.
- Cash & Current Investments was $737.0 million for Q1 2026 at Agios Pharmaceuticals, down from $854.4 million in the prior quarter.
- Across five years, Cash & Current Investments topped out at $1.0 billion in Q3 2024 and bottomed at $569.9 million in Q2 2024.
- A 5-year average of $797.8 million and a median of $783.1 million in 2022 frame the typical range for Cash & Current Investments.
- Annual changes were most pronounced in 2022 — Cash & Current Investments plunged 60.46% — and 2025, when it surged 64.76%.
- Agios Pharmaceuticals' Cash & Current Investments stood at $783.1 million in 2022, then retreated by 0.79% to $776.9 million in 2023, then increased by 15.03% to $893.7 million in 2024, then dropped by 4.4% to $854.4 million in 2025, then fell by 13.74% to $737.0 million in 2026.
- Business Quant data shows AGIO's Cash & Current Investments at $737.0 million in Q1 2026, $854.4 million in Q4 2025, and $952.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Cash & Current Investments (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 65,899.61 Bn | 65,899.33 Bn | - | 283.54 Mn |
| 2 | Nanobiotix | 1,933.82 Bn | 1,933.76 Bn | - | 61.40 Mn |
| 3 | Akari Therapeutics | 959.56 Bn | 959.56 Bn | - | - |
| 4 | BeOne Medicines | 471.67 Bn | 466.88 Bn | 1.35 Bn | 4.79 Bn |
| 5 | Vertex Pharmaceuticals | 122.32 Bn | 115.07 Bn | 2.59 Bn | 7.25 Bn |
| 6 | Regeneron Pharmaceuticals | 70.04 Bn | 61.29 Bn | 3.31 Bn | 8.75 Bn |
| 7 | Belite Bio | 62.06 Bn | 62.06 Bn | - | - |
| 8 | Argenx Se | 55.93 Bn | 50.74 Bn | 1.41 Bn | 5.18 Bn |
| 9 | Alnylam Pharmaceuticals | 37.55 Bn | 34.54 Bn | 959.66 Mn | 3.01 Bn |
| 10 | Agios Pharmaceuticals | 2.22 Bn | 1.49 Bn | 19.43 Mn | 737.04 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 737.04 Mn |
| Dec 31, 2025 | 854.43 Mn |
| Sep 30, 2025 | 952.86 Mn |
| Jun 30, 2025 | 938.94 Mn |
| Mar 31, 2025 | 893.38 Mn |
| Dec 31, 2024 | 893.71 Mn |
| Sep 30, 2024 | 1.00 Bn |
| Jun 30, 2024 | 569.89 Mn |
| Mar 31, 2024 | 597.99 Mn |
| Dec 31, 2023 | 776.93 Mn |
| Sep 30, 2023 | 647.49 Mn |
| Jun 30, 2023 | 702.57 Mn |
| Mar 31, 2023 | 739.20 Mn |
| Dec 31, 2022 | 783.12 Mn |
| Sep 30, 2022 | 727.68 Mn |
| Jun 30, 2022 | 819.31 Mn |
| Mar 31, 2022 | 923.53 Mn |
| Dec 31, 2021 | 1.02 Bn |
| Sep 30, 2021 | 1.27 Bn |
| Jun 30, 2021 | 1.67 Bn |